JP2023542523A5 - - Google Patents
Info
- Publication number
- JP2023542523A5 JP2023542523A5 JP2023518177A JP2023518177A JP2023542523A5 JP 2023542523 A5 JP2023542523 A5 JP 2023542523A5 JP 2023518177 A JP2023518177 A JP 2023518177A JP 2023518177 A JP2023518177 A JP 2023518177A JP 2023542523 A5 JP2023542523 A5 JP 2023542523A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antigen
- weeks
- binding fragment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082162P | 2020-09-23 | 2020-09-23 | |
| US63/082,162 | 2020-09-23 | ||
| US202063084900P | 2020-09-29 | 2020-09-29 | |
| US63/084,900 | 2020-09-29 | ||
| PCT/IB2021/058662 WO2022064399A1 (en) | 2020-09-23 | 2021-09-22 | Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542523A JP2023542523A (ja) | 2023-10-10 |
| JP2023542523A5 true JP2023542523A5 (https=) | 2024-10-04 |
Family
ID=80845024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518177A Pending JP2023542523A (ja) | 2020-09-23 | 2021-09-22 | 抗ｃｄ７３及び抗ｐｄ－ｌ１抗体並びに化学療法を使用する治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010746A1 (https=) |
| EP (1) | EP4217072A4 (https=) |
| JP (1) | JP2023542523A (https=) |
| KR (1) | KR20230074206A (https=) |
| CN (1) | CN116209468A (https=) |
| AU (1) | AU2021349415A1 (https=) |
| BR (1) | BR112023004594A2 (https=) |
| CA (1) | CA3194926A1 (https=) |
| IL (1) | IL301376A (https=) |
| WO (1) | WO2022064399A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4626552A1 (en) * | 2022-12-01 | 2025-10-08 | MedImmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3423494A1 (en) * | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| MY204117A (en) * | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019173692A2 (en) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| EP3947447A4 (en) * | 2019-04-02 | 2023-01-11 | Medimmune, LLC | ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY FOR THE TREATMENT OF TUMORS |
-
2021
- 2021-09-22 CA CA3194926A patent/CA3194926A1/en active Pending
- 2021-09-22 AU AU2021349415A patent/AU2021349415A1/en not_active Abandoned
- 2021-09-22 BR BR112023004594A patent/BR112023004594A2/pt unknown
- 2021-09-22 IL IL301376A patent/IL301376A/en unknown
- 2021-09-22 JP JP2023518177A patent/JP2023542523A/ja active Pending
- 2021-09-22 US US18/246,206 patent/US20240010746A1/en active Pending
- 2021-09-22 CN CN202180063881.XA patent/CN116209468A/zh active Pending
- 2021-09-22 KR KR1020237013299A patent/KR20230074206A/ko active Pending
- 2021-09-22 WO PCT/IB2021/058662 patent/WO2022064399A1/en not_active Ceased
- 2021-09-22 EP EP21871791.6A patent/EP4217072A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020147A5 (https=) | ||
| He et al. | Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo | |
| Jiang et al. | The inhibitory effects of xanthohumol, a prenylated chalcone derived from hops, on cell growth and tumorigenesis in human pancreatic cancer | |
| RU2007134571A (ru) | Комбинация и способы введения терапевтических средств и комбинированной терапии | |
| CN108135901A (zh) | 胆管癌的治疗 | |
| JP2017516802A (ja) | がんの治療におけるエリブリンの使用 | |
| JP2022536854A5 (https=) | ||
| JP2021522193A5 (https=) | ||
| Shen et al. | Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo | |
| JP2023542523A5 (https=) | ||
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| TW201929882A (zh) | Ｅ３連接酶抑制劑和溶瘤病毒在用於製備抗腫瘤藥物的用途 | |
| JP2021511344A5 (https=) | ||
| EP3960243A1 (en) | Pharmaceutical composition for preventing or treating treatment-resistant cancer | |
| Venturini et al. | A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer | |
| JP2024541900A5 (https=) | ||
| JP5605511B2 (ja) | 薬剤の併用による癌治療方法 | |
| Guo et al. | Blockade of calcium-activated chloride channel ANO1 ameliorates ionizing radiation-induced intestinal injury | |
| JP7278405B2 (ja) | 小細胞肺がんの治療におけるキアウラニブの使用 | |
| Cai et al. | Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer | |
| Sone et al. | Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study | |
| MOULTON et al. | Tumors in the urinary bladder of a monkey Induction with 2-nitronaphthalene | |
| JP2024519449A5 (https=) | ||
| Arnold et al. | Innovative therapeutic strategies to overcome radioresistance in breast cancer | |
| Tummarello et al. | Teniposide as single drug therapy for elderly patients affected by small cell lung cancer |